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451Oseltamivir and breastfeedingCorrespondenceOseltamivir is a selective inhibitor of influenza virus neur-
aminidase enzymes. In the case of an avian influenza pan-
demic, many breastfeeding women will potentially be
prescribed oseltamivir.1 Following oral administration, osel-
tamivir is absorbed and rapidly converted into the active
metabolite oseltamivir carboxylate.
We were consulted on the case of a healthy laboratory
assistant who had stung herself with an influenza H5N1 virus-
contaminated needle. She was treated with oseltamivir
75 mg bid for 5 days. At the time of the incident she was
breastfeeding her 9-month-old child twice a day. Since it was
unknown whether or not oseltamivir transfers into breast
milk, and that adverse effects to the suckling infant could not
be ruled out, we advised her to discontinue breastfeeding
during treatment.
To obtain information on the transfer of oseltamivir into
breast milk we asked the patient to collect samples during
her treatment period. These breast milk samples were col-
lected twice a day over the 5-day period, giving a total of
11 samples. She was instructed to completely empty her
breasts. The samples were analyzed by Roche.2
Figure 1 shows the concentration profiles of oseltamivir and
oseltamivir carboxylate in breast milk over the five consecu-
tive days of sampling. Oseltamivir concentrations fluctuated
over time. The active carboxylatemetabolite was notmeasur-
able in the first sample and reached steady-state concentra-
tions of 37 to 39 ng/ml after 3 days. At steady-state,
concentrations of metabolite were higher than those of osel-
tamivir, consistent with the reported higher metabolite than
oseltamivir plasma concentrations in healthy volunteers.3
After reaching a steady state, no continued accumulation of
oseltamivir carboxylate occurred in breast milk.
Internationally, the relative infant dose (RID), expressed
as a percentage of the weight-adjusted maternal dose, is
regarded as the most accurate tool to get an impression of the
infant’s daily dose as a result of exposure via breastfeeding.4Figure 1 The first oseltamivir tablet was taken one hour before
milk sampling. Thereafter oseltamivir was taken eight times
within 30 minutes before or after the time of milk sampling.
The last two milk samples were taken 4.5 and 13.5 hours,
respectively, after the last oseltamivir intake.A RID of less than 10% is generally considered safe for con-
tinuing breastfeeding.
Based on our data of breast milk levels, the maximum
concentration of oseltamivir (38.2 ng/ml) and the maximum
concentration of oseltamivir carboxylate expressed as
equivalent of oseltamivir (the molecular weight of oseltami-
vir divided by the molecular weight of oseltamivir carbox-
ylate times the maximum concentration of oseltamivir
carboxylate in the breast milk: 312.4/284.4  39.5 =
43.4 ng/ml) give a total exposure of 81.6 ng/ml to the infant
at maximum. This means that a fully breastfed infant would
drink at maximum 0.012 mg/kg/day (81.6 ng/ml times
150 ml/kg/day). If the mother’s weight is assumed to be
60 kg, she was treated with oseltamivir 2.5 mg/kg/day.
Therefore the RID at a maximum is 0.5% of the maternal
weight-adjusted dose. Since the maximum concentration of
oseltamivir is exceptionally high (see Figure 1), this can be
regarded as the ‘worst case scenario’.
Based on this case report, oseltamivir or oseltamivir
carboxylate exposure via breast milk is not expected to cause
clinically significant concentrations in the suckling infant.
Further studies in more nursing mothers are required to
verify the safety of oseltamivir during breastfeeding.
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